COMMUNIQUÉS West-GlobeNewswire

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
29/06/2026
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
29/06/2026
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim [...]
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
29/06/2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics [...]
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
29/06/2026
Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
HealthLynked Launches AI-Powered Healthcare Communication Platform Featuring 24/7 Appointment Scheduling and Medical Office AI Agents
29/06/2026
NAPLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK ), a leader in healthcare technology, patient engagement, and care coordination, today announced the launch of its next- [...]
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
29/06/2026
FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 Daily nomlabofusp increased and [...]
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
29/06/2026
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial [...]
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
29/06/2026
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage [...]
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
29/06/2026
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity
29/06/2026
Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide targeting microRNA- [...]
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
29/06/2026
The Royal Marsden NHS Foundation Trust activated as the second clinical site in the ZIMA-101 Phase 1 trial Patient identification, pre-screening and screening activities ongoing at first activated site Company remains [...]
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
29/06/2026
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already [...]
Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development
29/06/2026
Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases HELSINKI, June 29, 2026 (GLOBE [...]
Zelluna ASA: New share capital registered
29/06/2026
Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “ Company ”) on 18 June 2026 regarding a successfully placed private placement (the “ Private Placement ”) [...]
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
29/06/2026
Patient enrollment has been completed; all enrolled patients remain alive Data presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany - June 29, 2026 - [...]
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
29/06/2026
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. Powered [...]
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
29/06/2026
Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio Navtemadlin, an oral MDM2 inhibitor, has the [...]
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus [...]

Pages